GF

Gordon J. Freeman

DI Dana-Farber Cancer Institute: 7 patents #2 of 242Top 1%
Harvard University: 4 patents #11 of 527Top 3%
EU Emory University: 2 patents #4 of 126Top 4%
BH Brigham and Women's Hospital: 1 patents #37 of 199Top 20%
BC Beth Israel Deaconess Medical Center: 1 patents #13 of 79Top 20%
UP University of Pennsylvania: 1 patents #50 of 270Top 20%
CC Children'S Medical Center: 1 patents #24 of 170Top 15%
NA Novartis Ag: 1 patents #62 of 478Top 15%
📍 Brookline, MA: #11 of 502 inventorsTop 3%
🗺 Massachusetts: #253 of 13,863 inventorsTop 2%
Overall (2022): #17,068 of 548,613Top 4%
7
Patents 2022

Issued Patents 2022

Showing 1–7 of 7 patents

Patent #TitleCo-InventorsDate
11492403 Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof Vassiliki Boussiotis, Xia Bu, Vikram Juneja, Arlene H. Sharpe, Nikolaos Patsoukis +2 more 2022-11-08
11485787 Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof Rosemarie Dekruyff, Dale T. Umetsu, Sanhong Yu, Yanping Xiao 2022-11-01
11413340 Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gerhard Frey, Jennifer Marie Mataraza +2 more 2022-08-16
11359020 Agents that modulate immune cell activation and methods of use thereof Arlene H. Sharpe, Yanping Xiao, Loise M. Francisco, Rosemarie Dekruyff, Dale T. Umetsu 2022-06-14
11359013 Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway Arlene H. Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry 2022-06-14
11261251 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor Rafi Ahmed, Timothy David Jones, Francis Joseph Carr, James P. Gregson 2022-03-01
11220545 Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents Yanping Xiao 2022-01-11